🟢 IBRX is trading 7.2% up today after FDA accepts ANKTIVA sBLA for bladder cancer

IBRX is trading 7.2% up at $8.32 in pre-market after the FDA accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA.

• The filing seeks to expand ANKTIVA’s use with BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), boosting sentiment on the drug’s commercial potential.
• The move follows several days of range-bound trading for the stock, which closed the prior session at $7.76.